Maisons Alfort, France

Jean-Pierre Tafani


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2007

Loading Chart...
1 patent (USPTO):Explore Patents

Title: **Inventor Profile: Jean-Pierre Tafani**

Introduction

Jean-Pierre Tafani, an accomplished inventor based in Maisons-Alfort, France, holds a notable patent that signifies his contributions to the field of pharmacology. With a focus on innovative compounds, Tafani's work emphasizes the potential for therapeutic applications, particularly as hypnotics.

Latest Patents

Jean-Pierre Tafani is credited with one significant patent: "Dihydroimidazo[5.1-a]-beta-carboline derivatives, method for their preparation, and their application as a drug." This invention concerns dihydroimidazo[-a]-β-carboline compounds of general formula (I), characterized by various substituents (R), which may range from hydrogen and halogen atoms to more complex alkyl and aryl groups. The inventive compounds are primarily intended for medicinal use, enhancing their value in the medical field.

Career Highlights

Tafani's affiliation with Macef has allowed him to delve into the synthesis and application of these novel compounds, contributing to advancements in drug development. His expertise encompasses both the preparation of these compounds and their subsequent application in medicinal domains.

Collaborations

Throughout his career, Jean-Pierre Tafani has worked alongside several notable colleagues, including Jean-Bernard Fourtillan and Marianne Fourtillan. These collaborations have enriched his research and development efforts, showcasing a synergistic approach to innovation in the field.

Conclusion

Jean-Pierre Tafani's contributions to the domain of pharmaceuticals through his innovative patent underscore the importance of ongoing research and collaboration in the quest for medical advancements. His work not only reflects individual ingenuity but also highlights the potential impact of collaborative efforts in addressing critical healthcare challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…